Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Debt / NOTE 0.599% 8/0
-
Market price (% of par)
-
103.81%
-
Total 13F principal
-
$487,706,068
-
Principal change
-
+$19,902,911
-
Total reported market value
-
$508,853,510
-
Number of holders
-
46
-
Value change
-
+$21,852,590
-
Number of buys
-
25
-
Number of sells
-
20
Institutional Holders of BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 as of Q2 2019
As of 30 Jun 2019,
BIOMARIN PHARMACEUTICAL INC - NOTE 0.599% 8/0 was held by
46 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$487,706,068
in principal (par value) of the bond.
The largest 10 bondholders included
ADVENT CAPITAL MANAGEMENT /DE/, Allianz Asset Management GmbH, MACKAY SHIELDS LLC, LAZARD ASSET MANAGEMENT LLC, ZAZOVE ASSOCIATES LLC, SHENKMAN CAPITAL MANAGEMENT INC, SYMPHONY ASSET MANAGEMENT LLC, JPMORGAN CHASE & CO, Polar Capital LLP, and BAKER BROS. ADVISORS LP.
This page lists
46
institutional bondholders reporting positions
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.